Microparticle immune response modifier shows broad effects against recurrent or metasta...( DENVER CO and AUCKLAND NZ (April 21 ...)
DENVER, CO and AUCKLAND, NZ (April 21, 2009) MIS416, a novel microparticle-based immune response modifier, demonstrated the ability to significantly reduce the number and size of metastatic tumors in preclinical mouse models of lung and breast cancers, Innate Therapeutics (formerly Virionyx Corporation) announced. Research presented today at the American Association of Cancer Research (AACR) meeting in Denver, CO by researchers from the Auckland, NZ company and their colleagues at the David Geffen School for Medicine, University of California, Los Angeles showed that MIS416 significantly inhibited tumor growth and the formation of metastases when tested as a stand-alone agent. When administered as an adjunct to localized tumor irradiation, MIS416 also demonstrated synergistic activity against the recurrence of lung tumors. Moreover, in a therapeutic cancer vaccine model, MIS administered as a single agent significantly induced an anti-tumor cellular immune response without the reintroduction of previously harvested tumor antigens. This successful induction of adaptive immunity correlated with inhibition of tumor growth.
"On the basis of these findings, MIS416 appears to be a good candidate for clinical evaluation as an adjunct to existing cancer therapies such as surgery and radiation," said Gill Webster, Ph.D., chief scientific officer of Innate Therapeutics, who led the poster presentation. "In this clinical setting, MIS416 therapy may be able to contribute significantly towards limiting tumor reoccurrence or metastatic disease."
Immune response modifiers (IMRs) are agents that target the body's immune system to combat disease by mobilizing and expanding a broad range of intrinsic host defence mechanisms. Unlike first generation IMRs such as Toll-like receptor agonists or interferon alpha, each of which have a limited spectrum of activity and lack the ability to treat a broad range of malignant diseases, MIS416 acts on multiple pathways s
'/>"/>
| Contact: Joan Kureczka JKureczka@comcast.net 415-821-2413 Kureczka/Martin Associates Source:Eurekalert |
Related biology news :
1. Drug-embedded microparticles bolster heart function in animal studies
2. Device protects transplanted pancreatic cells from the immune system
3. Vitamin D may exacerbate autoimmune disease
4. New evidence explains poor infant immune response to certain vaccines, says MU researcher
5. Lombardi research: Monoclonal antibodies primed to become potent immune weapons against cancer
6. A paradigm shift in immune response regulation
7. New origin found for a critical immune response
8. HIV adapts to escape immune response
9. Frogs immune system is key in fight against killer virus
10. La Jolla Institute signs exclusive license agreement with Medimmune on major asthma discovery
11. Molecule that suppresses immune response under study in type 1 diabetes
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |